Lyell Immunopharma (LYEL) AI Stock Analysis

• Market Cap: $210.55M
• Dividend Yield: N/A
• Average Volume (3M): 57.17K
• Price to Earnings (P/E): ―
• Beta (1Y): 2.00
• Revenue Growth: 11.11%
• EPS Growth: -46.50%
• Country: US
• Employees: 300
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -2.89
• Shares Outstanding: 19,211,203
• 10 Day Avg. Volume: 28,993
• 30 Day Avg. Volume: 57,170
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: -0.47
• Enterprise Value/Revenue: -1.66K
• Enterprise Value/Gross Profit: -1.66K
• Enterprise Value/Ebitda: 0.50
• 1Y Price Target: $11.00
• Price Target Upside: 0.36% Upside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 3

• Rating: 54 Neutral
• Price Target: $11.00 ▲(0.36% Upside)

Lyell Immunopharma's overall stock score reflects a challenging financial situation with no revenue and ongoing losses, balanced by positive corporate events and moderate technical indicators. The recent funding and promising clinical trial data are significant positives, but the company's valuation remains low due to negative earnings.

Positive Factors

Clinical data

LYL314 has shown promising early complete responses lasting at least 6 months, equating to ~51% of all treated patients maintaining durable complete responses for six months.

Regulatory progress

RMAT designation for LYL314 is a positive sign in turbulent times at the FDA.

Negative Factors

Clinical development risks

Increasing competition among CAR-T products for B cell lymphomas as well as personnel changes at the FDA may increase the risk of clinical development.

Financial performance

Lyell reported a net loss of $0.69 per share, which was worse than the analyst's estimate of a net loss of $0.18 per share.

Market competition

The CD19-targeted CAR-T space is considered crowded and may not support another entrant with the current under $3 billion aggregated annual sales across competitors.

Lyell Immunopharma Business Overview & Revenue Model

Company Description

Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845, that targets multiple solid tumors; and NY-ESO-1 for synovial sarcoma and other solid tumor indications. The company entered into research and development collaboration and license agreement with GlaxoSmithKline for NY-ESO-1 program. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

How the Company Makes Money

Lyell Immunopharma generates revenue primarily through strategic collaborations and partnerships with pharmaceutical and biotechnology companies. These partnerships often involve licensing agreements, milestone payments, and royalties associated with the development and commercialization of T-cell therapies. Additionally, Lyell may receive funding from grants and research collaborations aimed at advancing their scientific innovations. The company also invests in developing proprietary technologies and seeks to monetize these innovations through clinical success, leading to potential product sales and additional partnerships.

Lyell Immunopharma Financial Statement Overview

Summary

Lyell Immunopharma is facing substantial financial challenges, primarily due to its inability to generate revenue and persistent operational losses. The balance sheet is relatively stronger, with a manageable level of debt and a good equity base. However, the company's cash flow situation is strained, with heavy reliance on financing for liquidity. Overall, the financial position reflects high operational risk and the need for strategic shifts to improve revenue and profitability.

Income Statement

Lyell Immunopharma has faced significant challenges in revenue generation, with revenue dropping to zero in the latest year. The company has consistently reported negative net income, resulting in negative net profit margins. The absence of revenue and persistent losses indicate financial difficulties in scaling operations or commercializing products.

Balance Sheet

The balance sheet shows a strong equity position with a low debt-to-equity ratio, reflecting financial prudence. However, the decline in stockholders' equity over the years may indicate operational challenges. The equity ratio remains healthy, suggesting solid capital management despite operational losses.

Cash Flow

Lyell Immunopharma's cash flow statement highlights significant operating cash outflows due to ongoing losses. While free cash flow remains negative, the company has maintained a consistent level of cash reserves. The ability to generate positive cash flow from financing activities has been crucial in sustaining operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	60.00K	61.00K	130.00K	84.68M	10.65M	7.76M
Gross Profit	60.00K	61.00K	130.00K	68.22M	-3.88M	281.00K
EBITDA	-199.95M	-200.64M	-226.76M	-166.65M	-199.94M	-207.64M
Net Income	-331.40M	-342.99M	-234.63M	-4.75M	-285.50M	-198.53M
Balance Sheet
Total Assets	385.45M	490.86M	750.03M	937.56M	1.13B	908.28M
Cash, Cash Equivalents and Short-Term Investments	276.79M	370.53M	546.22M	640.15M	614.79M	612.62M
Total Debt	46.60M	58.97M	63.17M	67.70M	67.82M	54.57M
Total Liabilities	86.53M	108.03M	95.08M	104.31M	197.62M	189.84M
Stockholders Equity	298.92M	382.82M	654.95M	833.25M	929.79M	718.44M
Cash Flow
Free Cash Flow	-172.00M	-162.86M	-166.38M	-193.83M	-191.75M	-212.35M
Operating Cash Flow	-171.48M	-162.39M	-163.69M	-169.56M	-126.25M	-160.87M
Investing Cash Flow	137.54M	122.42M	184.05M	-11.54M	-121.57M	-273.52M
Financing Cash Flow	621.00K	1.33M	1.74M	10.63M	401.24M	476.79M

Lyell Immunopharma Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 10.96
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LYEL, the sentiment is Positive. The current price of 10.96 is below the 20-day moving average (MA) of 10.97, above the 50-day MA of 10.37, and below the 200-day MA of 11.95, indicating a neutral trend. The MACD of 0.09 indicates Positive momentum. The RSI at 55.92 is Neutral, neither overbought nor oversold. The STOCH value of 72.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LYEL.

Lyell Immunopharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LYEL	54 Neutral	$210.55M	―	-76.59%	―	11.11%	-46.50%
ADCT	54 Neutral	$356.62M	―	123.38%	―	15.73%	38.73%
FDMT	52 Neutral	$304.97M	―	-38.87%	―	―	―
Sector *	51 Neutral	$7.83B	-0.18	-40.10%	2.29%	21.46%	-2.03%
SEER	49 Neutral	$117.19M	―	-25.25%	―	12.13%	-8.23%
FATE	44 Neutral	$128.02M	―	-52.11%	―	-31.23%	14.92%
NKTX	39 Underperform	$156.25M	―	-26.94%	―	―	26.33%

Lyell Immunopharma Corporate Events

Lyell Immunopharma Secures $100 Million in Private Placement

On July 24, 2025, Lyell Immunopharma entered into a Securities Purchase Agreement to raise up to $100 million through a private placement with institutional and accredited investors. The initial closing, expected around July 25, 2025, will generate approximately $50 million, with the potential for an additional $50 million upon achieving specific clinical or corporate milestones within a year. The proceeds will fund pivotal-stage clinical trials of LYL314 and support general corporate purposes, with expectations to sustain operations into mid-2027. This financial move positions Lyell to advance its clinical trials and potentially submit a Biologics License Application in 2027 for LYL314 in treating large B-cell lymphoma.

Lyell Immunopharma Announces Promising CAR T-Cell Trial Data

On June 17, 2025, Lyell Immunopharma announced new clinical data from its ongoing Phase 1/2 trial of LYL314, a CAR T-cell therapy for large B-cell lymphoma (LBCL). The trial showed promising results with high overall response rates and manageable safety profiles in both third- or later-line (3L+) and second-line (2L) settings. The company plans to initiate a randomized pivotal trial by early 2026 and has the manufacturing capacity to support clinical development and early commercial launch if approved.

Lyell Immunopharma Expands Board, Appoints New Director

On June 9, 2025, Lyell Immunopharma‘s Board of Directors expanded from seven to eight members, appointing Mark Bachleda, Pharm.D., M.B.A., as a Class I director. Dr. Bachleda will serve until the 2028 annual stockholders meeting, receiving compensation and equity grants as per the company’s policy, adjusted for a recent reverse stock split.

Lyell Immunopharma Announces 1-for-20 Reverse Stock Split

On May 27, 2025, Lyell Immunopharma announced a reverse stock split at a 1-for-20 ratio, authorized by its stockholders during the annual meeting on May 15, 2025. Effective May 30, 2025, this move will consolidate every 20 shares into one, adjusting stock options and equity plans proportionately, with trading on a split-adjusted basis starting June 2, 2025, on Nasdaq. This action aims to streamline the company’s stock structure without altering shareholders’ proportional ownership.